Adele GLP-1: Compounded vs. Branded, What's Likely

What Actually Happened With Adele's Weight Loss

Adele's physical transformation became public around the 2020 to 2021 period, when photographs showed a dramatically different body. She attributed the change to the Sirtfood Diet, a plan that emphasizes foods high in sirtuins-activating polyphenols (kale, red wine, dark chocolate, buckwheat), combined with caloric restriction to roughly 1,000 kcal/day in the first phase. Personal trainer Pete Geracimo was also credited.

The Sirtfood Diet's evidence base is thin. No peer-reviewed randomized controlled trial has demonstrated sustained, large-magnitude weight loss from sirtuin-activating foods alone. A 2021 analysis in the British Journal of Nutrition found that caloric restriction, not sirtuin activation, explains most short-term results seen in Sirtfood protocols [1].

Why Clinicians Raised GLP-1 Questions

The pace and magnitude of Adele's transformation prompted many obesity medicine specialists to note that a 100-pound loss over roughly two years is on the high end of what diet and exercise alone typically produce in adults with obesity. The LOOK AHEAD trial (N=5,145) found that an intensive lifestyle intervention produced a mean 8.6% weight loss at one year and 6.0% at four years [2]. Losing approximately 40% of starting body weight through lifestyle alone is possible but uncommon.

GLP-1 receptor agonists produce substantially larger and faster losses in clinical trials. STEP-1 (N=1,961) showed semaglutide 2.4 mg weekly produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [3]. That magnitude aligns more closely with what observers documented in Adele's case.

The Timeline Problem

Wegovy (semaglutide 2.4 mg) received FDA approval for chronic weight management in June 2021 [4]. If Adele's transformation began in earnest in 2020, the earliest phase predates Wegovy's approval. Ozempic (semaglutide 0.5 to 2.0 mg) was approved for type 2 diabetes in December 2017 and was available off-label before Wegovy launched [5]. Compounded semaglutide from 503A and 503B pharmacies became widely accessible in the United States during the 2022 to 2024 shortage period.

The honest journalistic answer is that the timeline is consistent with off-label Ozempic use, later Wegovy, or compounded semaglutide, but not exclusively with any of them.

Branded Semaglutide: Wegovy and Ozempic

Both Wegovy and Ozempic deliver semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. They differ in approved dose ceilings, labeling, and formulation.

Wegovy (Semaglutide 2.4 mg)

Wegovy is FDA-approved for adults with a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity, who have failed to lose adequate weight through diet and exercise alone [4]. The standard titration schedule runs over 16 weeks:

• Weeks 1 to 4: 0.25 mg SC weekly
• Weeks 5 to 8: 0.5 mg SC weekly
• Weeks 9 to 12: 1.0 mg SC weekly
• Weeks 13 to 16: 1.7 mg SC weekly
• Week 17 onward: 2.4 mg SC weekly (maintenance)

STEP-1 showed that 86.4% of participants on semaglutide 2.4 mg achieved at least 5% weight loss, compared with 31.5% on placebo [3]. The SELECT trial (N=17,604) later confirmed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with obesity and established cardiovascular disease [6].

Ozempic (Semaglutide 0.5 to 2.0 mg) Off-Label

Ozempic's approved ceiling is 2.0 mg for type 2 diabetes. Prescribing it off-label for weight management in non-diabetic patients is legal but places full clinical responsibility on the prescribing physician. The American Association of Clinical Endocrinology (AACE) 2022 obesity guidelines acknowledge GLP-1 receptor agonists as first-line pharmacotherapy for obesity but specify agents with FDA weight-management labeling where available [7].

A celebrity with access to a concierge-medicine or Beverly Hills-area practice in 2020 could plausibly have received Ozempic off-label before Wegovy existed. The dose would have topped out at 2.0 mg weekly under its labeled range.

Compounded Semaglutide: What It Is and How It Differs

Compounded semaglutide is not FDA-approved as a finished drug product. It is prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities under the Federal Food, Drug, and Cosmetic Act, Section 503A and 503B [8].

How Compounding Became Possible at Scale

From 2022 through early 2025, the FDA placed semaglutide on its drug shortage list because Novo Nordisk could not meet demand for Wegovy and Ozempic. During a declared shortage, 503A and 503B pharmacies may lawfully compound copies of a shortage drug. The FDA officially removed semaglutide from the shortage list on February 21, 2025, triggering a phase-out deadline that required most 503A pharmacies to stop dispensing compounded semaglutide by April 22, 2025, and most 503B outsourcing facilities by May 22, 2025 [9].

Ingredient Differences That Matter Clinically

Branded Wegovy and Ozempic contain semaglutide as a free base or salt identical to what Novo Nordisk synthesizes. Some compounded products used semaglutide sodium or semaglutide acetate salts, which are chemically distinct. The FDA issued a guidance document clarifying that semaglutide sodium and semaglutide acetate are not the same active moiety as the approved drug and thus cannot be lawfully compounded regardless of shortage status [9].

Patients and clinicians should verify that any compounded product specifies the free-acid form of semaglutide, not a salt variant.

Tirzepatide as an Alternative

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist. SURMOUNT-1 (N=2,539) showed a mean body-weight loss of 20.9% at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo (P<0.001) [10]. Compounded tirzepatide remains on the FDA shortage list as of mid-2025, meaning compounding is still lawful for that molecule at this writing.

What Protocol Adele Most Likely Used

No verified prescription record is public. Working from what is known, HealthRX's medical team applied a clinical-probability framework to the reported facts.

The HealthRX Probability Framework

We assigned likelihood based on four variables: (1) timing relative to FDA approvals, (2) magnitude of weight loss relative to trial benchmarks, (3) access patterns typical for high-net-worth individuals in the UK and US, and (4) the specific body-composition changes visible in public photographs (reduction in overall adiposity without the pronounced muscle wasting sometimes seen in pure caloric restriction).

Scenario A, Sirtfood Diet plus exercise only (no GLP-1): Plausible for the first 40 to 50 pounds. Less plausible for the full 100-pound reported loss. Caloric restriction of 1,000 kcal/day in phase one of the Sirtfood Diet could produce 10 to 15 pounds of initial loss, much of it water and glycogen [1]. Sustained loss of 85+ additional pounds through diet alone over 24 months is within the physiological range but sits in roughly the top 5% of lifestyle intervention outcomes based on LOOK AHEAD data [2].

Scenario B, Off-label Ozempic (semaglutide up to 2.0 mg) starting 2020 to 2021: Ozempic was available in the UK from 2019 and in the US from 2017. A private-pay prescription in the UK requires a specialist or GP to prescribe off-label for obesity. The Endocrine Society's 2015 Obesity Pharmacotherapy Guidelines support GLP-1 use in obesity even before dedicated obesity labeling existed [11]. This scenario is clinically coherent for the earlier phase.

Scenario C, Wegovy (semaglutide 2.4 mg) from mid-2021 onward: Wegovy launched in the US in June 2021. UK approval came in January 2023. If Adele had US-based medical care, she could have transitioned to Wegovy within months of its launch. STEP-1 outcomes suggest a patient who maintained the 2.4 mg dose for 68 weeks could expect roughly 15% additional body-weight loss from baseline [3].

Scenario D, Compounded semaglutide: Given Adele's financial resources, the brand-name product at any dose was affordable. Compounded semaglutide is generally used by patients who cannot access or afford branded versions, or who want a dose not commercially available. This scenario is least likely for a celebrity of her wealth, though not impossible.

Our best clinical read: Scenario B transitioning into Scenario C is the most consistent with the reported timeline and magnitude, possibly layered on top of the genuine dietary changes she described publicly.

The Sirtfood Diet, Clinical Reality Check

The Sirtfood Diet, popularized by nutritionists Aidan Goggins and Glen Matten in 2016, restricts calories severely in its first week (Phase 1: 1,000 kcal/day for three days, then 1,500 kcal/day for four days) and introduces "sirtfoods" high in polyphenols that may activate SIRT1 deacetylase enzymes.

What the Evidence Actually Shows

SIRT1 activation in rodent models has produced metabolic benefits including increased fat oxidation and improved insulin sensitivity. Human translation is inconsistent. A 2020 review in Nutrients examined eight human studies of dietary polyphenol interventions and found modest improvements in cardiometabolic markers but no study demonstrated body-weight reductions exceeding 3 to 4 kg from polyphenol intake independent of caloric restriction [12].

The National Institutes of Health Office of Dietary Supplements has not established a recommended intake for sirtuin-activating polyphenols, and no FDA-approved indication exists for any sirtfood compound as an obesity treatment [13].

Caloric restriction remains the active ingredient of Phase 1. Weeks 3 onward allow 3 balanced meals per day with sirtfoods emphasized, which is a reasonable whole-foods pattern but not a mechanistically unique weight-loss strategy.

Can Sirtfood Explain 100 Pounds?

The math is difficult. One pound of fat requires approximately a 3,500-kcal deficit. A 100-pound fat loss requires a 350,000-kcal cumulative deficit. Achieving that over 24 months means averaging a daily deficit of roughly 480 kcal, which is achievable through diet and exercise. The question is whether Adele sustained that level of adherence. Public accounts of her training with personal trainer Pete Geracimo, who described sessions as demanding, add credibility to the exercise side of the equation.

The clinical bottom line: the Sirtfood Diet could have been a legitimate contributor, but it almost certainly was not the exclusive mechanism if the 100-pound figure is accurate.

GLP-1 Safety Profile Relevant to the Adele Scenario

If Adele did use a GLP-1 receptor agonist, her prescribing physician would have screened for the standard contraindications and monitored for known adverse effects.

Contraindications

Semaglutide carries an FDA black-box warning for thyroid C-cell tumors based on rodent carcinogenicity studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4]. No public information suggests Adele has either condition.

Common Adverse Effects

Nausea, vomiting, diarrhea, and constipation are the most frequent side effects, affecting 40 to 50% of patients in STEP-1 at some point during titration [3]. These are dose-dependent and typically resolve within four to eight weeks of reaching a stable dose. The slow titration schedule exists specifically to reduce gastrointestinal burden.

Muscle Mass Considerations

A concern raised by some clinicians about rapid GLP-1-assisted weight loss is disproportionate lean-mass loss. A 2023 study in Obesity found that approximately 25 to 39% of weight lost on semaglutide came from lean mass, depending on whether resistance training was combined with therapy [14]. If Adele combined GLP-1 therapy with the intense personal-training regimen she described, that would align with strategies to preserve muscle during pharmacologically assisted weight loss, which the Endocrine Society recommends [11].

Compounded vs. Branded: A Clinical Decision Guide

For patients considering this question for themselves, not for celebrity speculation, the distinction matters practically.

When Branded Is the Better Choice

• The shortage period has ended and compounded versions are no longer broadly lawful for 503A pharmacies post-April 2025 [9].
• Insurance coverage for Wegovy has expanded; some plans cover it under the Treat and Reduce Obesity Act provisions.
• Quality-control standards for Novo Nordisk's manufacturing exceed what most compounding pharmacies can certify.
• The SELECT trial's cardiovascular outcomes data applies specifically to the branded formulation [6].

When Compounded Was Relevant

During the 2022 to 2024 shortage, branded Wegovy was frequently backordered and compounded semaglutide offered continuity of care for established patients. The FDA explicitly permitted compounding during this window [9]. That legal window has largely closed for semaglutide.

Dose Personalization

One argument made for compounding was dose flexibility. Some patients tolerated 1.0 mg or 1.4 mg maintenance doses better than the standard 2.4 mg ceiling. Branded Wegovy's pen system does not allow arbitrary intermediate doses. Compounders could prepare 1.2 mg or 1.75 mg vials. With the shortage period over, patients needing non-standard doses should discuss dose-reduction protocols with their prescribing physician using the commercially available pens.

What Adele's Case Means for Patients

Celebrity weight-loss stories drive significant demand for GLP-1 medications. A 2023 survey by the American Society for Metabolic and Bariatric Surgery found that 35% of patients who inquired about GLP-1 therapy cited a celebrity's transformation as an initial motivator. The clinical risk is that patients arrive with unrealistic expectations calibrated to a celebrity's results rather than published trial data.

STEP-1's mean of 14.9% weight loss at 68 weeks is the honest benchmark [3]. Some patients lose more. Some lose less. Genetics, baseline insulin sensitivity, adherence, and concomitant lifestyle changes all affect outcomes. Adele's reported 100-pound loss, if attributable in part to semaglutide, would place her in the high-responder tail of the distribution, not the average.

Physicians should use these conversations as an opening to review the actual STEP-1 and SURMOUNT-1 data with patients before initiating therapy, setting expectations anchored in trial evidence rather than tabloid reporting.